Tocilizumab in the treatment of systemic juvenile idiopathic arthritis

Tocilizumab in the treatment of systemic juvenile idiopathic arthritis

Miho Murakami,1 Minako Tomiita,2,3 Norihiro Nishimoto11Laboratory of Immune Regulation, Wakayama Medical University, Wakayama, 2Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, 3Department of Allergy and Rheumatology, Chiba Children&#39;s Hospital, Chiba, Japan...

Full description

Bibliographic Details
Main Authors:	Murakami M, Tomiita M, Nishimoto N
Format:	Article
Language:	English
Published:	Dove Medical Press 2012-07-01
Series:	Open Access Rheumatology: Research and Reviews
Online Access:	http://www.dovepress.com/tocilizumab-in-the-treatment-of-systemic-juvenile-idiopathic-arthritis-a10313

Similar Items

Rapid desensitisation to tocilizumab in systemic idiopathic juvenile arthritis
by: Rosalaura Villarreal González, et al.
Published: (2021-03-01)

Comparison of different treatment modalities of tocilizumab in children with systemic juvenile idiopathic arthritis
by: M. M. Kostik, et al.
Published: (2013-09-01)

2.1 Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis (JIA)
by: Yokota S, et al.
Published: (2008-09-01)

Tocilizumab-effects on growth impairment in systemic juvenile idiopathic arthritis
by: Yokota Shumpei, et al.
Published: (2011-09-01)

Tocilizumab in the treatment of systemic-onset juvenile idiopathic arthritis – single-centre experience
by: Justyna Roszkiewicz, et al.
Published: (2018-10-01)

Safety and efficacy of tocilizumab treatment in children with systemic onset of juvenile idiopathic arthritis
by: Sleptsova T, et al.
Published: (2011-09-01)

THE CLINICAL AND PARACLINICAL EFFICACY OF TOCILIZUMAB IN JUVENILE IDIOPATHIC ARTHRITIS
by: Ninel REVENCO, et al.
Published: (2021-06-01)

TOCILIZUMAB EFFICACY AND SAFETY IN PATIENTS WITH SEVERE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
by: E.I. Alexeeva, et al.
Published: (2011-05-01)

TOCILIZUMAB EFFICACY AND SAFETY IN PATIENTS WITH SEVERE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
by: E.I. Alexeeva, et al.
Published: (2011-01-01)

Tocilizumab-induced hypofibrinogenemia in patients with systemic-onset juvenile idiopathic arthritis
by: Tingyan He, et al.
Published: (2023-06-01)

Sequential Tocilizumab and Tofacitinib Treatment for Systemic Juvenile Idiopathic Arthritis: a Case Report
by: Ye Zhang, et al.
Published: (2022-11-01)

THE PHENOMENON OF NEUTROPENIA DURING TOCILIZUMAB THERAPY IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS
by: M. I. Kaleda, et al.
Published: (2018-01-01)

Efficacy and safety of tocilizumab in european children with systemic onset juvenile idiopathic arthritis
by: Hofer M, et al.
Published: (2011-09-01)

Posterior reversible encephalopathy syndrome during treatment with tocilizumab in juvenile idiopathic arthritis
by: Marcos Rosa Júnior, et al.

EXPERIENCE IN APPLICATION OF TOCILIZUMAB AT SYSTEM VARIANT OF JUVENILE IDIOPATHIC ARTHRITIS IN THE REPUBLIC OF BASHKORTOSTAN
by: V. А. Malievskii, et al.
Published: (2014-05-01)

The use of tocilizumab in a child with systemic onset juvenile idiopathic arthritis and ganglioneuroblastoma
by: Srdjan Pasic, et al.
Published: (2011-09-01)

Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review
by: Claudia Iannone, et al.
Published: (2023-02-01)

Tocilizumab for juvenile idiopathic arthritis: a single-center case series
by: Fatma Yazılıtaş, et al.
Published: (2020-03-01)

A HISTORY CASE OF TOCILIZUMAB USAGE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
by: R. V. Denisova, et al.
Published: (2012-07-01)

Cost–utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand
by: Nitichen Kittiratchakool, et al.
Published: (2020-09-01)

Experience of the Tocilizumab Application in Systemic Onset Juvenile Arthritis
by: A. V. Krasnopol’skaja, et al.
Published: (2015-11-01)

Case reports Juvenile idiopathic arthritis complicated by amyloidosis with secondary nephrotic syndrome – effective treatment with tocilizumab
by: Małgorzata Kwiatkowska, et al.
Published: (2015-08-01)

Retrospective Analysis of Efficacy and Safety of Tocilizumab Treatment in Children with Severe Systemic Juvenile Idiopathic Arthritis: 12-month Follow-up
by: A. A. Baranov, et al.
Published: (2013-03-01)

CLINICAL CASE OF USING TOCILIZUMAB FOR A FEMALE PATIENT WITH AN EARLY DEBUT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
by: О. L. Lomakina, et al.
Published: (2014-10-01)

Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
by: Masaki Shimizu, et al.
Published: (2020-01-01)

Tocilizumab in Systemic Juvenile Idiopathic Arthritis: Response Differs by Disease Duration at Medication Initiation and by Phenotype of Disease
by: Xin Yan, et al.
Published: (2021-11-01)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data
by: Espada G, et al.
Published: (2011-09-01)

The Use of Tocilizumab in 40 Patients With Polyarticular Juvenile Idiopathic Arthritis: the Results of a Retrospective Study
by: Mikhail M. Kostik, et al.
Published: (2017-06-01)

Tocilizumab in management of refractory juvenile idiopathic arthritis, 10 years of experience at tertiary university hospital
by: Mohammed A. Muzaffer, et al.
Published: (2021-07-01)

Health-economic analysis of tocilizumab in patients with rheumatoid arthritis and systemic juvenile arthritis
by: A. S. Kolbin, et al.
Published: (2020-05-01)

ADALIMUMAB IN TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
by: R. V. Denisova, et al.
Published: (2013-12-01)

PROGNOSTIC FACTORS FOR THE RESPONSE TO TOCILIZUMAB THERAPY IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS: A COHORT STUDY
by: Ekaterina I. Alexeeva, et al.
Published: (2018-07-01)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
by: De Benedetti Fabrizio, et al.
Published: (2012-07-01)

EFFICACY AND SAFETY OF TOCILIZUMAB IN CHILDREN WITH SYSTEMIC JUVENILE ARTHRITIS IN CLINICAL PRACTICE
by: M. I. Kaleda, et al.
Published: (2015-04-01)

Evaluation of the efficiency and safety of tocilizumab therapy in patients with systemic-onset juvenile idiopathic arthritis: results of a retrospective follow-up
by: M. M. Kostik, et al.
Published: (2018-01-01)

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
by: Gerd Horneff, et al.
Published: (2017-11-01)

TOCILIZUMAB IN THE TREATMENT OF CHILDREN WITH SYSTEMIC JUVENILE ARTHRITIS: ANALYSIS OF FACTORS INFLUENCING THE THERAPY EFFICIENCY IN THE LONG TERM
by: M. I. Kaleda, et al.
Published: (2015-04-01)

Current Treatments for Juvenile Idiopathic Arthritis
by: Alberto eMartini, et al.
Published: (2011-10-01)

EXPERIENCE WITH ABATACEPT IN TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS
by: Margarita Fedorovna Dubko, et al.
Published: (2012-10-01)

Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review
by: Ju-Yang Jung, et al.
Published: (2018-12-01)